A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies.Yongheng Liu, Jingyi Wang, Jian Xu et al.|Journal of Clinical Oncology|2020Cited by 50
A phase I study of safety and pharmacokinetics of A166, a novel selective inhibitor of human epidermal growth factor receptor-2 in Chinese patients with advanced solid tumors.Yongheng Liu, Jingyi Wang, Wei Lian et al.|Journal of Clinical Oncology|2020Cited by 3